Spectrum Pharmaceuticals (NasdaqGS:SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the appointment of Brian Holzer to the position of Executive Director of Brand Management. Dr. Holzer will report to Rick Gonzalez, Vice President of Business Solutions and Government Affairs. He will be primarily responsible for leading and managing Spectrum’s cross-functional brand efforts for FUSILEV^® and ZEVALIN^® as well as brand planning for apaziquone and belinostat, Spectrum’s late-stage drugs in development.

“We believe Dr. Holzer will be an immediate value-added member of the Spectrum Pharmaceuticals commercial organization as we continue to grow the FUSILEV and ZEVALIN brands and prepare for the additions of apaziquone and belinostat over the next 12-18 months,” said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals. “We believe Brian’s education in medicine and business administration, along with his hands on experience in successfully building on a hematology/oncology franchise at Amgen with regard to NEUPOGEN^®/Neulasta^® will have an immediate positive impact on our commercial organization.”

Dr. Holzer comes to Spectrum with significant experience in the health care industry and a proven track record of high performance. At Amgen, he was most recently the Director of Strategy and Operations for the NEUPOGEN^®/Neulasta^® franchise in the Oncology Business Unit, and primarily was responsible for brand planning, budget management, and data analytics. Previously, Brian held positions of increasing responsibility on the NEUPOGEN/Neulasta^® promotions team and was a key contributor to innovative branded and unbranded marketing campaigns. Brian started his tenure at Amgen as a sales representative for Enbrel^® in the New York/New Jersey metro area.

Dr. Holzer earned his Bachelor of Science in General Science from Pennsylvania State University, his MD from the Drexel School of Medicine and his MBA from The Wharton School of Business with a focus in Health Care Management. Prior to Wharton, Brian worked as a medical resident in the University of Pennsylvania Health System before joining the Reed Smith law firm as an internal medical consultant on pharmaceutical litigation cases including Prempro^® and Vioxx^®.

About Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology. The Company’s strategy is comprised of acquiring, developing and commercializing a broad and diverse pipeline of late-stage clinical and commercial products. The Company markets two oncology drugs, FUSILEV and ZEVALIN and has two drugs, apaziquone and belinostat, in late stage development along with a diversified pipeline of novel drug candidates. The Company has assembled an integrated in-house scientific team, including clinical development, medical research, regulatory affairs, biostatistics and data management, formulation development, and has established a commercial infrastructure for the marketing of its drug products. The Company also leverages the expertise of its worldwide partners to assist in the execution of its strategy. For more information, please visit the Company’s website at www.sppirx.com.

source:Spectrum Pharmaceuticals, Inc.